430 East 29th Street / New York, NY
8 rue de la Croix Jarry / 75013 Paris
2500 Sumner Boulevard / Raleigh, NC
10 articles with Cellectis
Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer
Cellectis S.A. announced the first preclinical data on UCARTMESO, its allogeneic CAR-T cell product candidate targeting mesothelin
Shares of Xencor, Inc. are down nearly 6% after the company announced Novartis terminated its rights to develop vibecotamab, a CD123 x CD3 blood cancer bispecific.
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021
Cellectis S.A. today announced results for the three-month and nine-month periods ending September 30, 2021.
Cellectis Announces Release of Abstracts at ASH Showcasing Updated Preliminary Clinical Data from BALLI-01 Study and First Preclinical Data from TALGlobin01
Cellectis S.A., a gene-editing company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor -T cells and gene therapy programs for genetic diseases, announced the release of two abstracts, which were accepted for presentation at the 63rd American Society of Hematology Annual Meeting taking place from December 11-14, 2021.
Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), announced today that pre-clinical data that support anti-tumor activity of UCARTMESO will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021).
Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities
Cellectis S.A., a clinical-stage biotechnological company employing its core proprietary technologies to develop products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells in the field of immuno-oncology and gene-edited hematopoietic stem cells in other therapeutic indications, featured the Cellectis Innovation Days, a company event held on May 24-28, virtually.
Cellectis S.A. held its Annual Shareholders’ General Meeting on June 1, 2021 at its head office in Paris, France.
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS). Dear Shareholders, In the context of the Covid-19 pandemic and in accordance with Ordinance no. 2020-321 of March 25, 2020, the provisions of which were extended until July 31, 2021 by Decree no. 2021-255 of March 9, 2021, this general meeting will be held in closed session, i.e. without the physical presence of the shareholders and persons who are usually able to attend.
Cellectis S.A., a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells in the field of immuno-oncology, announced that it has completed sales of approximately $47 million of American Depositary Shares pursuant to the Company’s ATM program established on March 29, 2021, through Jefferies LLC, acting as sales agent.
Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells in the field of immuno-oncology, today announced that it has filed a prospectus supplement with the Securities and Exchange Commission (“SEC”) relating to an At-